Depigmented-polymerised allergoids favour regulatory over effector T cells: enhancement by 1α, 25-dihydroxyvitamin D3

[1]  D. Robinson,et al.  Depigmented-polymerised allergoids favour regulatory over effector T cells: enhancement by 1α, 25-dihydroxyvitamin D3 , 2014, BMC Immunology.

[2]  C. Hawrylowicz,et al.  The role of 1α,25‐dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+and IL‐10+ CD4+ T cells , 2012, European journal of immunology.

[3]  C. Hawrylowicz,et al.  Serum 25-dihydroxyvitamin D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma. , 2012, The Journal of allergy and clinical immunology.

[4]  O. Pfaar,et al.  A randomized placebo‐controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy * , 2012, Allergy.

[5]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy , 2012, Clinical and Translational Allergy.

[6]  R. Ėmužytė,et al.  Immunotherapy with depigmented‐polymerized mixed tree pollen extract: a clinical trial and responder analysis , 2010, Allergy.

[7]  D. Robinson,et al.  Efficacy, safety, and immunological effects of a 2‐year immunotherapy with Depigoid® birch pollen extract: a randomized, double‐blind, placebo‐controlled study , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  L. Klimek,et al.  Safety of a Depigmented, Polymerized Vaccine for the Treatment of Allergic Rhinoconjunctivitis and Allergic Asthma , 2010, American journal of rhinology & allergy.

[9]  P. Briza,et al.  Depigmented and Polymerised House Dust Mite Allergoid: Allergen Content, Induction of IgG4 and Clinical Response , 2010, International Archives of Allergy and Immunology.

[10]  Daniel M. Altmann,et al.  Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression , 2009, The Journal of experimental medicine.

[11]  P. Briza,et al.  Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula alba , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  E. Hickman,et al.  Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. , 2009, The Journal of clinical investigation.

[13]  P. Henricks,et al.  1α,25-Dihydroxyvitamin D3 Potentiates the Beneficial Effects of Allergen Immunotherapy in a Mouse Model of Allergic Asthma: Role for IL-10 and TGF-β1 , 2008, The Journal of Immunology.

[14]  J. Larsen,et al.  Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[15]  J. Garcia-Robaina,et al.  Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. , 2006, The Journal of allergy and clinical immunology.

[16]  J. Bousquet,et al.  Standards for practical allergen‐specific immunotherapy , 2006, Allergy.

[17]  C. Akdis.  Future of allergen-specific immunotherapy: better understanding of the mechanisms, novel treatments, and long-term cure. , 2006, Immunology and allergy clinics of North America.

[18]  P. Kalinski,et al.  Analysis of the CD4+ T cell responses to house dust mite allergoid , 2003, Allergy.

[19]  E. Grage‐griebenow,et al.  T Cell Reactivity with Allergoids: Influence of the Type of APC , 2000, The Journal of Immunology.

[20]  H. Fiebig,et al.  Reactivity of T Cells with Grass Pollen Allergen Extract and Allergoid , 1999, International Archives of Allergy and Immunology.

[21]  B. Haselden,et al.  Immunoglobulin E–independent Major Histocompatibility Complex–restricted T Cell Peptide Epitope–induced Late Asthmatic Reactions , 1999, The Journal of experimental medicine.

[22]  Jarman,et al.  Responses of human birch pollen allergen‐reactive T cells to chemically modified allergens (allergoids) , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[23]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[24]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[25]  R. Patterson,et al.  Modified forms of allergen immunotherapy. , 1985, The Journal of allergy and clinical immunology.

[26]  J. Carnés,et al.  Skin tests with native, depigmented and glutaraldehyde polymerized allergen extracts. , 2005, Journal of investigational allergology & clinical immunology.